EMYRIA LIMITED — Investor Relations & Filings

Emyria Limited is a clinical-stage biotechnology company focused on developing and delivering new treatments for mental health and neurological conditions. The company integrates clinical service delivery with data-driven drug development to accelerate the path to market for novel therapies. Emyria operates a network of specialist clinics that provide evidence-based care while collecting high-quality real-world data to inform its drug discovery pipeline. Key focus areas include MDMA-assisted therapy for post-traumatic stress disorder (PTSD) and the development of proprietary cannabinoid-based medicines. Through its partnership with clinical research organizations and mental health specialists, the company aims to provide scalable, data-backed solutions for complex health challenges. Its proprietary data platform supports the identification of new drug targets and the optimization of clinical trial designs.